Who is sponsoring NCT01959035?

NCT01959035 is sponsored by H. Lundbeck A/S.

What condition does NCT01959035 study?

NCT01959035 studies Schizophrenia.

What drugs are being tested in NCT01959035?

Interventions: Aripiprazole once-monthly.

What is the status of NCT01959035?

NCT01959035 is currently COMPLETED.

Last reviewed 2017-02-08 · How we verify

Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia

NCT01959035 Phase 3 COMPLETED Results posted

To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.

Details

Lead sponsor	H. Lundbeck A/S
Phase	Phase 3
Status	COMPLETED
Enrolment	88
Start date	2013-10
Completion	2015-03

Conditions

Schizophrenia

Interventions

Aripiprazole once-monthly

Primary outcomes

Safety and Tolerability — Up to 24 weeks and 4-week safety follow up
Number of treatment emergent adverse events (TEAEs).

Countries

United States